Providers/Grant Support
This activity was supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc.
Credits Available
- Physicians — maximum of 0.25 AMA PRA Category 1 Credits™
- Nurses — 0.25 Nursing Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity is designed to meet the professional educational needs of community-based medical oncologists, hematologists, urologists, nurse practitioners and physician assistants who treat and/or manage patients with genitourinary cancers.
Program Overview
Triplet therapy with ADT, docetaxel, and an androgen receptor signaling inhibitor is now a standard of care in mHSPC. Identifying when and how to integrate triplet regimens into prostate cancer care can be challenging. In this 15-minute educational activity, use interactive case scenarios to make difficult decisions about how to adapt treatment based on patient characteristics, manage treatment-emergent adverse events, and provide life-long care for patients with mHSPC.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify key patient-specific factors, including disease volume, timing of metastasis, and fitness, that influence treatment decisions in mHSPC.
- Apply evidence-based strategies to manage adverse events and improve adherence to triplet therapy protocols.
Faculty
Andrew J Armstrong, MD, ScM, FACP
Professor of Medicine, Surgery, Pharmacology and Cancer Biology
Director of Research, Duke Cancer Institute Center for Prostate and Urologic Cancers
Division of Medical Oncology
Departments of Medicine and Urology
Duke University
Durham, North Carolina
Alicia K. Morgans, MD, MPH, FASCO
Associate Professor
Harvard Medical School
Director, Survivorship Program
Dana-Farber Cancer Institute
Boston, Massachusetts
Joseph Park, MD - Case Creation
Clinical Faculty
Department of Internal Medicine
Division of Medical Oncology
Duke Raleigh Cancer Center
Raleigh, North Carolina
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and QDcme. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours
Disclosures of Conflict of Interest
Andrew J Armstrong, MD, ScM, FACP
Advisory Board: Astellas, Pfizer, Bayer, Janssen, BMS, AstraZeneca, Merck, Exelixis, Novartis, Medscape, Telix, Duality Bio, MedIQ, IDEOlogy, Sumitomo, and Precede Bio
Research: Astellas, Pfizer, Bayer, Janssen, BMS, AstraZeneca, Merck, Pathos, Amgen, Novartis, Fibrogen (to Duke)
Alicia K. Morgans, MD, MPH, FASCO
Advisory Board: Astellas, AstraZeneca, BMS, Bayer, Curium, Exact Sciences, Lantheus, Merck, Johnson & Johnson, Novartis, Pfizer, Telix, Tolmar
Joseph Park, MD
Advisory Board: MedScape, Ideology Health
Research: Tempus
The PIM planners and others have nothing to disclose. The QDcme planners and others have nothing to disclose
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be immediately available to the participant.
Disclosure of Unlabeled Use
PIM requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected].